NCT01927627View on ClinicalTrials.gov

Enzalutamide in Patients With High-risk Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 11, 2013

Primary Completion Date

March 29, 2017

Study Completion Date

April 26, 2017

Conditions
Adenocarcinoma of the Prostate
Interventions
DRUG

enzalutamide

oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT01927627 - Enzalutamide in Patients With High-risk Prostate Cancer | Biotech Hunter | Biotech Hunter